3
4
5
6
7
TREATMENT
Dry eyes
Dry mouth
Other glandular manifestations
Extraglandular manifestations
8 EPIDEMIOLOGY
9 MARKETED DRUGS
10 Approvals by country
11 PIPELINE DRUGS
12 KEY UPCOMING EVENTS
13 LICENSING AND ASSET ACQUISITION DEALS
14 OSE Immunotherapeutics Licenses IL-7 Antagonist To Servier
15 PARENT PATENTS
16 CLINICAL TRIAL LANDSCAPE
17 Sponsors by status
18 Sponsors by phase
19 BIBLIOGRAPHY
20 Prescription information
21 APPENDIX
LIST OF FIGURES
Figure 1: Trends in prevalent cases of primary Sjögren’s syndrome, 2016–25
Figure 2: Overview of pipeline drugs for Sjögren’s syndrome in the US
Figure 3: Pipeline drugs for Sjögren’s syndrome, by company
Figure 4: Pipeline drugs for Sjögren’s syndrome, by drug type
Figure 5: Pipeline drugs for Sjögren’s syndrome, by classifications
Figure 6: Key upcoming events in Sjögren’s syndrome
Figure 7: Licensing and asset acquisition deals in Sjögren’s syndrome, 2012–17
Figure 8: Parent patents in Sjögren’s syndrome
Figure 9: Clinical trials in Sjögren’s syndrome
Figure 10: Top 10 drugs for clinical trials in Sjögren’s syndrome
Figure 11: Top 10 companies for clinical trials in Sjögren’s syndrome
Figure 12: Trial locations in Sjögren’s syndrome
Figure 13: Sjögren’s syndrome trials status
Figure 14: Sjögren’s syndrome trials sponsors, by phase
LIST OF TABLES
Table 1: Prevalent cases of primary Sjögren’s syndrome, 2016–25
Table 2: Prevalent cases of primary Sjögren’s syndrome, by gender, 2016
Table 3: Prevalence of primary Sjögren’s syndrome, by gender, 2016
Table 4: Marketed drugs for Sjögren’s syndrome
Table 5: Approvals by country for Sjögren's syndrome
Table 6: Pipeline drugs for Sjögren’s syndrome in the US
Ask to Expertise @
https://www.reportsworldwide.com/enquiry?report_id=42611